Investigations and Practical Applications Highlight Transpara Breast AI’s Influence on Cancer Identification and Breast Imaging Efficiency
CHICAGO, Nov. 30, 2025 — is presenting its market-leading Transpara Breast AI suite, an integrated set of tools encompassing Detection, Density, and Temporal Comparison, at the 111th Annual Radiological Society of North America (RSNA) Annual Meeting, taking place from November 30 to December 4, 2025 (South Hall #4719). As the most clinically validated Breast AI available, Transpara Breast AI is designed for enterprise workflows, offering radiologists a ‘second set’ of eyes to aid in earlier cancer detection, alleviate radiologist burden, and enhance program efficacy.
The year 2025 has been significant for ScreenPoint Medical. With over 11 million mammograms processed, Transpara Breast AI is implemented in more than 30 countries at prominent healthcare facilities and has been adopted by 40% of the top 20 hospitals recognized in the 2025 US News and World Report’s Best Hospitals Honor Roll.
Furthermore, Transpara Breast AI has been selected to participate in the only randomized controlled trials (RCTs) within the Breast AI domain: the RCT in Sweden and the forthcoming $16 million RCT in the United States, which is scheduled to begin in early 2026 and is spearheaded by researchers at UCLA and UC Davis. Results from MASAI, published earlier this year, indicated a 29% improvement in cancer detection and a 44% reduction in screen-reading workload when Transpara Detection was utilized compared to the standard approach.
Risk assessment also constitutes a primary focus at RSNA 2025: Transpara Risk, an image-based 5-year risk prediction model for breast cancer, and Transpara Detection are the subjects of a compelling new investigation, “” (S5-SSBR02-4, Sunday, November 30, 2:30 PM, S406A). This research illustrates the enhanced value of risk prediction for precise care, with Transpara solutions demonstrating superior performance over both RSNA CAD and Mirai. AI-powered risk analysis reinforces ScreenPoint Medical’s dedication to women globally by supporting personalized prevention strategies and facilitating earlier diagnosis for less invasive treatment. Transpara Risk is presently approved for investigational use only.
Beyond Sunday’s session, the clinical and operational advantages of Transpara Breast AI will be highlighted in notable presentations and posters throughout the RSNA week:
- The investigation, “” (T3-SSBR05-6, Tuesday, December 2, 9:30 AM, S406A) marks the initial study to compare commercial AI algorithms for screening DBT using the same extensive dataset. The findings revealed notable performance differences among some of the four commercial AI algorithms, with Transpara Detection surpassing its competitors.
- The poster, “” (M5A-SPBR, Monday, December 1, 12:15 PM, Learning Center) proposes that Transpara Detection may have contributed to the earlier identification of 38% of interval breast cancers, particularly those overlooked or underestimated by radiologists. Research was conducted at Johns Hopkins Medicine.
- The study, “” (T3-SSBR05, Tuesday, December 2, 9:30 AM, S406A) demonstrates that Transpara Breast AI achieves greater specificity when incorporating prior examinations for analysis.
- The poster, “” (W5B-SPBR-3, Wednesday, December 3, 12:45 PM, Learning Center) showcases initial positive outcomes of its clinical implementation within a busy screening mammography practice. Transpara Detection exhibited strong capabilities in stratifying cancer risk and assisting recall decisions. Research was conducted at Johns Hopkins Medicine.
- The study, “” (R1-SSBR10, Thursday, December 4, 8:00 AM, S406A) indicated that an innovative AI-driven imaging biomarker for pre-reading of DBT can reliably identify approximately one-third of normal DBT screening examinations with a negative predictive value approaching 100%. This could enable pre-reading in screening, potentially allowing radiologists to accelerate the review of this category of DBT exams, thereby safely boosting radiologist efficiency and reducing workload.
“We are convinced that research translates into tangible outcomes in the real world. The pioneering research presented this week at RSNA 2025, alongside our ongoing investigations across breast imaging RCTs, substantiates the reality that Transpara Breast AI is enhancing the benchmark of care,” stated Pieter Kroese, CEO of ScreenPoint Medical. “Our collaborators, our performance, and our product are the reasons why healthcare leaders consistently select Transpara Breast AI. We anticipate productive discussions and progress at radiology’s premier conference.”
To learn more about the leading Breast AI solutions available, visit Booth #4719 (South Hall) at RSNA 2025 or arrange an online product demonstration following the event at
About ScreenPoint Medical
In the struggle against breast cancer, every image presents an opportunity: to uncover insights, to reveal risk, to represent health, to empower lives. We develop AI-powered technology for each phase of the breast imaging process, enhancing consistency, decreasing uncertainty, elevating patient experience, and transforming opportunities into concrete results.
Validated through research, propelled by innovation, and specifically designed for those striving for leadership in breast health, ScreenPoint’s Transpara Breast AI is trusted by radiologists and women globally. We are Breast AI. Discover more at
SOURCE ScreenPoint Medical